Roche And Eli Lilly Win FDA Clearance For Elecsys pTau217, Opening A New Alzheimer’s Blood-Test Step

Roche and Eli Lilly have secured FDA clearance for Elecsys pTau217, a blood test for Alzheimer’s disease that the companies are positioning as a simpler entry point into amyloid-pathology assessment. The test is designed to detect phosphorylated Tau 217 protein, a hallmark of Alzheimer’s disease that has been linked to amyloid plaque buildup in the brain.

According to Roche, high levels indicate a greater likelihood that a patient has Alzheimer’s disease, while low levels can help rule out the disease in people experiencing cognitive impairment. The test is intended for people ages 55 years or older with signs, symptoms or complaints of cognitive decline associated with Alzheimer’s disease, and it can be used across primary and secondary care settings.

What the clearance changes

Roche said the assay is the first FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings. That matters because Alzheimer’s diagnostics have typically depended on PET imaging or cerebrospinal fluid biomarkers, which neurologist Jared R. Brosch of Indiana University Health said can confirm amyloid pathology but may be costly, invasive and not readily accessible for many patients.

The commercial implication is less about novelty alone than about care-pathway reach. A blood test that can be used outside specialist centers could widen access to earlier evaluation, particularly if clinicians treat it as a triage tool before moving to more burdensome confirmatory methods.

The road here

Both companies also received European approval for this test back in May. The newly cleared assay is the second Alzheimer’s blood test from Roche and Lilly.

Last July, the companies won European approval for an earlier Elecsys blood test designed to help rule out Alzheimer’s disease by detecting phosphorylated tau-181 protein. That earlier test was approved by the FDA in February.

Taken together, the sequence suggests Roche and Lilly are building an Alzheimer’s diagnostics franchise incrementally: first a test aimed at ruling out disease, then a pTau217 assay that the companies say supports both rule-in and rule-out use. That progression gives them a stronger position in a market where the practical value of a test depends on whether it can fit routine care, not just specialist workups.